501666-23-5 Usage
Uses
Used in Pharmaceutical Industry:
PD 312237 is used as a research compound for studying the effects and mechanisms of pregabalin, its degradation products, and their potential applications in the treatment of neurological disorders. PD 312237 can be utilized in laboratory settings to investigate the pharmacological properties, safety, and efficacy of pregabalin and its related compounds.
Used in Neurological Applications:
PD 312237 may be used as a potential therapeutic agent for neurological conditions, given its origin as a degradation product of pregabalin. It could be explored for its potential effects on seizure control, pain management, and anxiety reduction, as well as its possible role in modulating the GABAergic system, which is involved in various neurological functions.
Used in Drug Development:
As a degradation product of pregabalin, PD 312237 can be used in the development of new drugs or drug formulations with improved pharmacokinetic and pharmacodynamic properties. Researchers can study its chemical structure and interactions to design more effective and safer medications for the treatment of neurological disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 501666-23-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,0,1,6,6 and 6 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 501666-23:
(8*5)+(7*0)+(6*1)+(5*6)+(4*6)+(3*6)+(2*2)+(1*3)=125
125 % 10 = 5
So 501666-23-5 is a valid CAS Registry Number.
501666-23-5Relevant academic research and scientific papers
Pregabalin lactose conjugates
-
, (2008/06/13)
In accordance with the present invention, there is provided pregabalin lactose conjugate compounds. Also provided as part of the present invention is a novel method of central nervous system disorders or diseases including seizure disorders, pain, depression, anxiety, sleep disorders, consumptive disorders, psychosis, tardive dyskinesia, Huntington's disease, or Parkinson's disease in a subject by administering to the subject a pharmaceutically effective amount of a pregabalin lactose conjugate.
